Marzi Andrea, Robertson Shelly J, Haddock Elaine, Feldmann Friederike, Hanley Patrick W, Scott Dana P, Strong James E, Kobinger Gary, Best Sonja M, Feldmann Heinz
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Science. 2015 Aug 14;349(6249):739-42. doi: 10.1126/science.aab3920. Epub 2015 Aug 6.
The latest Ebola virus (EBOV) epidemic spread rapidly through Guinea, Sierra Leone, and Liberia, creating a global public health crisis and accelerating the assessment of experimental therapeutics and vaccines in clinical trials. One of those vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (VSV-EBOV), a live-attenuated vector with marked preclinical efficacy. Here, we provide the preclinical proof that VSV-EBOV completely protects macaques against lethal challenge with the West African EBOV-Makona strain. Complete and partial protection was achieved with a single dose given as late as 7 and 3 days before challenge, respectively. This indicates that VSV-EBOV may protect humans against EBOV infections in West Africa with relatively short time to immunity, promoting its use for immediate public health responses.
最新的埃博拉病毒（EBOV）疫情在几内亚、塞拉利昂和利比里亚迅速蔓延，引发了全球公共卫生危机，并加速了对临床试验中实验性治疗方法和疫苗的评估。其中一种疫苗基于表达EBOV糖蛋白的重组水疱性口炎病毒（VSV-EBOV），这是一种具有显著临床前疗效的减毒活载体。在此，我们提供临床前证据，证明VSV-EBOV能完全保护猕猴免受西非EBOV-Makona毒株的致死性攻击。分别在攻击前7天和3天给予单剂量疫苗，可实现完全和部分保护。这表明VSV-EBOV可能以相对较短的免疫时间保护人类免受西非EBOV感染，从而促进其用于即时的公共卫生应对。
